The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior

Archives of Suicide Research

Volumn 12, Issue 4, 2008, Pages 299-308

  Sher, Leo ^a   Stanley, Barbara H ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Endogenous opioids; Endorphin; Non suicidal self injury; Suicide

Indexed keywords

NARCOTIC ANTAGONIST;

ARTICLE; AUTOMUTILATION; EVIDENCE BASED MEDICINE; HUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; RISK FACTOR; SUICIDE ATTEMPT;

EVIDENCE-BASED MEDICINE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SUICIDE, ATTEMPTED;

EID: 53349161755     PISSN: 13811118     EISSN: 15436136     Source Type: Journal    
DOI: 10.1080/13811110802324748     Document Type: Article

References (80)

1. Akil, H., Watson, S. J., Young, E., et al. (1984). Endogenous opioids: Biology and function. Annual Review of Neuroscience, 7, 223-255.
2. Bayne, K., Haines, D., Dexter, S., et al. (1995). Nonhuman primate wounding prevalence: A retrospective analysis. Lab Animal, 24, 40-44.
3. Bongar, B., Peterson, L. G., Golann, S., et al. (1990). Self-mutilation and the chronically suicidal patient: An examination of the frequent visitor to the psychiatric emergency room. Annals of Clinical Psychiatry, 2, 217-222.
4. Bouvard, M. P., Leboyer, J. M., Launay, J., et al. (1995). Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: A double-blind, placebo-controlled study. Psychiatry Research, 58, 191-201.
5. Casner, J. A., Weinheimer, B., & Gualtieri, C. T. (1996). Naltrexone and self-injurious behavior: A retrospective population study. Journal of Clinical Psychopharmacology, 16, 389-394.
6. Cazzullo, A. G., Musetti, M. C., Musetti, L., et al. (1999). Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. European Neuropsycholopharmacology: Journal of the European College of Neuropsychopharmacology, 9, 361-363.
7. Chishti, P., Stone, D. H., Corcoran, P., et al. (2003). Suicide mortality in the European Union. European Journal of Public Health, 13, 108-114.
8. Coccaro, E. F. & Siever, L. J. (1995). The neuropsychopharmacology of personality disorders. In F. E. Bloom & D.J. Kupfer (Eds.), Psychopharmacology: The fourth generation of progress (pp. 1567-1579). New York: Raven Press.
9. Coid, J., Allolio, B., & Rees, L. H. (1983). Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet, 2, 545-546.
10. Crosy, A. E., Cheltenham, M. P., & Sacks, J. J. (1999). Incidence of suicidal ideation and behavior in the United States, 1994. Suicide and Life Threatening Behavior, 29, 131-140.
11. Cross, A. J., Hille, C., & Slater, P. (1987). Subtraction autoradiography of opiate receptor subtypes in human brain, Brain Research, 418(2), 343-348.
12. Duman, E. N., Kesim, M., Kadioglu, M., et al. (2004). Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. Journal of Pharmacology Sciences, 94, 161-165.
13. Ernst, M., Devi, L., Silva, R. R., et al. (1993). Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacology Bulletin, 29, 221-227.
14. Evans, C. & Lacey, J. H. (1992). Multiple self-damaging behaviour among alcoholic women. A prevalence study. British Journal of Psychiatry, 161, 643-647.
15. Favazza, A. R. (1989). Why patients mutilate themselves. Hospital & Community Psychiatry, 40, 137-145.
16. Favazza, A. R. (1998). The coming of age of self-mutilation. Journal of Nervous and Mental Disease, 186, 259-268.
17. Favazza, A. R. & Conterio, K. (1989). Female habitual self-mutilators. Acta Psychiatrica Scandinavica, 79, 283-289.
18. Feldman, M. D. (1988). The challenge of self-mutilation: a review. Comprehensive Psychiatry, 29, 252-269.
19. Fichter, M. M., Quadflieg, N., & Rief, W. (1994). Course of multi-impulsive bulimia. Psychological Medicine, 24, 591-604.
20. Frances, A., Fyer, M., & Clarkin, J. (1986). Personality and suicide. Annals of the New York Academic of Sciences, 487, 281-293.
21. Fyer, M. R., Frances, A. J., Sullivan, T., et al. (1988). Suicide attempts in patients with borderline personality disorder. American Journal of Psychiatry, 145, 737-739.
22. Gabilondo, A. M., Meana, J. J., & García-Sevilla, J. A. (1995). Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Research, 682(1-2), 245-250.
23. González-Maeso, J., Rodríguez-Puertas, R., Meana, J. J. (2002). Quantitative stoichiometry of G-proteins activated by mu-opioid receptors in postmortem human brain. European Journal of Pharmacology, 452(1), 21-33.
24. Griengl, H., Sendera, A., Dantendorfer, K. (2001). Naltrexone as a treatment of self-injurious behavior - a case report. Acta Psychiatrica Scandinavica, 103, 234-236.
25. Gross-Isseroff, R., Dillon, K. A., Israeli, M., et al. (1990). Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Research, 530(2), 312-316.
26. Ha, H., Tan, E. C., Fukunaga, H., et al. (1981). Naloxone reversal of acupuncture analgesia in the monkey. Experimental Neurology, 73, 298-303.
27. Hamon, M., Gozlan, H., Bourgoin, S., et al. (1987). Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology, 26(6), 531-539.
28. Hirschfeld, R. M. & Russell, J. M. (1997). Assessment and treatment of suicidal patients. New England Journal of Medicine, 337, 910-915.
29. Hughes, D. H. (1995). Can the clinician predict suicide? Psychiatric Services, 46, 449-451.
30. Kalin, N. H., Shelton, S. E., & Barksdale, C. M. (1988). Opiate modulation of separation-induced distress in non-human primates. Brain Research, 440(2), 285-292.
31. Kalin, N. H., Shelton, S. E., & Barksdale, C. M. (1989). Behavioral and physiologic effects of CRH administered to infant primates undergoing maternal separation. Neuropsychopharmacology, 2(2), 97-104.
32. Kars, H., Broekema, W., Glaudemans-van Gelderen, I., et al. (1990). Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biological Psychiatry, 27, 741-746.
33. Kemperman, I., Russ, M. J., & Shearin, E. (1997). Self-injurious behavior and mood regulation in borderline patients. Journal of Personality Disorder, 11, 146-157.
34. Lacey, J. H. & Evans, C. D. (1986). The impulsivist: a multi-impulsive personality disorder. British Journal of Addiction, 81(5), 641-649.
35. Liu J. L., Han, X. W., & Su, S. N. (1990). The role of frontal neurons in pain and acupuncture analgesia. Science in China. Series B, Chemistry, Life Sciences & Earth Sciences, 33, 938-945.
36. Mann, J. J. (2002). A current perspective on suicide and attempted suicide. Annals of Internal Medicine 136, 302-311.
37. Marinus, L. M., Chase, W. K., & Novak, M. A. (2000). Self-biting behavior in rhesus macaques (Macaca mulatta) is preferentially directed to body areas associated with acupuncture analgesia. American Journal of Primatology, 51, 71-72.
38. Mercer, D. (2007). Medications in the treatment of borderline personality disorder 2006. Current Psychiatry Reports 9, 53-62.
39. Mogil, J. S., Wilson, S. G., Chesler, E. J., et al. (2003). The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4867-4872.
40. Nock, M. K., Joiner, T. E., Gordon, K., et al. (2006). Non-suicidal self-injury among adolescents: Diagnostic correlates and relation to suicide attempts. Psychiatry Research, 144, 65-72.
41. Quirarte, G. L., Galvez, R., Roozendaal, B., et al. (1998). Norepinephrine release in the amygdala in response to footshock and opioid peptidergic drugs. Brain Research, 808(2), 134-140.
42. Reisine, T. & Pasternak, G. (1996). Opioid analgesics and antagonists. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, & A. G. Gilman (Eds.), The pharmacological basis of therapeutics (pp. 521-556). New York: McGraw-Hill.
43. Roth, A. S., Ostroff, R. B., & Hoffman, R. E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviounan open-label trial. Journal of Clinical Psychiatry, 57, 233-237.
44. Roy, A. (1978). Self-mutilation. British Journal of Medical Psychology, 51, 201-203.
45. Russ, M. J., Roth, S. D., Kakuma, T., et al. (1994). Pain perception in self-injurious borderline patients: naloxone effects. Biological Psychiatry, 35, 207-209.
46. Russ, M. J., Campbell, S. S., Kakuma, T., et al. (1999). EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research, 89, 201-214.
47. Russ, M. J., Roth, S. D., Lerman, A., et al. (1992). Pain perception in self-injurious patients with borderline personality disorder. Biological Psychiatry, 32, 501-511.
48. Russ, M. J., Shearin, E. N., Clarkin, J. F., et al. (1993). Subtypes of self-injurious patients with borderline personality disorder. American Journal of Psychiatry, 150, 1869-1871.
49. Sandman, C. A., Hetrick, W. P., Taylor, D. V., et al. (1993). Naltrexone reduces self-injury and improves learning. Experimental and Clinical Psychopharmacology, 1, 242-258.
50. Sandman, C. A., Hetrick, W. P., Taylor, D. V., et al. (1997). Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. American Journal on Mental Retardation, 102, 182-199.
51. Sandman, C. A., Hetrick, W., Talyor, D., et al. (2000). Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury. Peptides, 21, 785-791.
52. Sandman, C. A., Thompson, T., Barrett, R. P. et al. (1998). Opiate blockers. In M. Aman & S. Reiss (Eds.), Consensus handbook on psychopharmacology (pp. 291-302). Unpublished handbook, Ohio State University, Nisonger Center.
53. Sandman, C. A., Touchette, P., Lenjavi, M., et al. (2003). Beta-Endorphin and ACTH are dissociated after self-injury in adults with developmental disabilities. American Journal on Mental Retardation, 108(6), 414-424.
54. Scarone, S., Gambini, O., Calabrese, G., et al. (1990). Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data. Psychiatry Research, 32(2), 159-166.
55. Schmahl, C. G., McGlashan, T. H., & Bremner, J. D. (2002). Neurobiological correlates of borderline personality disorder. Psychopharmacology Bulletin, 36, 69-87.
56. Schmauss, C. (1987). Spinal kappa-opioid receptor-mediated antinociception is stimulus specific. European Journal of Pharmacology, 137, 197-205.
57. Scifo, R., Cioni, M., Nicolosi, A., Batticane, N., et al. (1996). Opioid-immune interactions in autism: Behavioural and immunological assessment during a double-blind treatment with naltrexone. Annali Dell'istituto Superiore Di Sanita, 32, 351-359.
58. Shearer, S. L. (1994). Phenomenology of self-injury among inpatient women with borderline personality disorder. Journal of Nervous and Mental Disease, 182, 524-526.
59. Simeon, D., Stanley, B., Frances, A., et al. (1992). Self-mutilation in personality disorders: Psychological and biological correlates. American Journal of Psychiatry, 149, 221-226.
60. Sonne, S., Rubey, R., Brady, K., et al. (1996). Naltrexone treatment of self-injurious thoughts and behaviors. Journal of Nervous and Mental Disease, 184, 192-195.
61. Stanley, B. & Brodsky, B. (2005). Suicidal and self-injurious behavior in borderline personality disorder: The self-regulation action model, In J. Gunderson, & P. Hoffman (Eds.), Borderline personality disorder perspectives: From professional to family member sharing knowledge.....building partnerships. Washington, DC: American Psychiatric Press.
62. Steiner, H. & Gerfen, C. R. (1998). Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental Brain Research, 123(1-2), 60-16
63. Stone, M., Hurt, S., & Stone, D. (1987). The PI 500: Long-term follow-up of borderline inpatients meeting DSM-III criteria I. Global outcomes. Journal of Personality Disorders, 1, 291-298.
64. Stone, M. H. (1990). The fate of borderline patients: Success, outcome, and psychiatric practice. New York/ London: The Guilford Press.
65. Symons, F. J. & Thompson, T. (1997). Self-injurious behaviour and body site preference. Journal of Intellectual Disability Research, 41, 456-468.
66. Symons, F. J., Thompson, A., & Rodriguez, M. C. (2004). Self-injurious behavior and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews, 10, 193-200.
67. Thompson, T., Hackenberg, T., Cerutti, D., et al. (1994). Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of medication effects. American Journal on Mental Retardation, 99, 85-102.
68. Tiefenbacher, S., Marinus, L. M., Davenport, M. D., et al. (2003). Meyer: Evidence for a endogenous opioid involvement in the expression of self-injurious behavior in rhesus monkeys. American Journal of Primatology, 60, 103.
69. Tiefenbacher, S., Novak, M. A., Lutz, C. K., et al. (2005). The physiology and neurochemistry of self-injurious behavior: A nonhuman primate model. Frontiers in Bioscience, 10, 1-11.
70. Träskman-Bendz, L., Ekman, R., Regnéll, G., et al. (1992). HPA-related CSF neuropeptides in suicide attempters. European Neuropsychopharmacology, 2(2), 99-106.
71. Ulett, G. A., Han, S., & Han, J. S. (1998). Electroacupuncture: Mechanisms and clinical application. Biological Psychiatry, 44, 129-138.
72. Wallenstein, M. B. & Nock, M. K. (2007). Physical exercise for the treatment of non-suicidal self-injury: Evidence from a single-case study. American Journal of Psychiatry, 164, 350-351.
73. Watkins, L. R. & Mayer, D. J. (1982). Involvement of spinal opioid systems in footshock-induced analgesia: antagonism by naloxone is possible only before induction of analgesia. Brain Research, 242(2), 309-326.
74. Winchel, R. M. & Stanley, M. (1991). Self-injurious behavior: A review of the behavior and biology of self-mutilation. American Journal of Psychiatry, 148, 306-317.
75. World Health Organization. (2001). Burden of mental and behavioral disorders. In: The World Health Report 2001. Mental Health: New Understanding New Hope (pp. 19-45). Geneva: World Health Organization.
76. Yamamoto, M., Komori, T., Matsumoto, T., et al. (2003). Effects of single and repeated prolonged stress on mu-opioid receptor mRNA expression in rat gross hypothalamic and midbrain homogenates. Brain Research, 980(2), 191-196.
77. Zalsman, G., Molcho, A., Huang, Y., et al. (2005). Postmortem mu-opioid receptor binding in suicide victims and controls. Journal of Neural Transmission, 112(7), 949-954.
78. Zubieta, J. K., Smith, Y. R., Bueller, J. A., et al. (2002). Mu-opioid receptor-mediated antinociceptive responses differ in men and women. Journal of Neuroscience, 22(12), 5100-5107.
79. Zubieta, J. K., Ketter, T. A., Bueller, J. A., et al. (2003a). Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Archives of General Psychiatry, 60(11), 1145-1153.
80. Zubieta, J. K., Heitzeg, M. M., Smith, Y. R., et al. (2003b). COMT vall58met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science, 299(5610), 1240-1243.